Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7044167 | 1.00 | CA2 (0.52) | CA2HSD17B2CA1PDCD1CD274 | |
| SCHEMBL11695590 | 0.81 | PDCD1 (0.43) | PDCD1CD274POLBGAAATM | |
| SCHEMBL7041284 | 0.80 | SIGMAR1 (0.55) | POLBSIGMAR1 | |
| SCHEMBL1823141 | 0.80 | SIGMAR1 (0.55) | POLBSIGMAR1 | |
| SCHEMBL23023068 | 0.80 | SIGMAR1 (0.55) | POLBSIGMAR1 | |
| Bromide SCHEMBL11696799 | 0.80 | PDCD1 (0.42) | PDCD1CD274POLBGAAATM | |
| SCHEMBL6487410 | 0.79 | CNR1 (0.56) | OPRK1SIGMAR1 | |
| SCHEMBL6487403 | 0.79 | CNR1 (0.56) | OPRK1SIGMAR1 | |
| SCHEMBL11696442 | 0.77 | ALOX15 (0.54) | GAAATMSIGMAR1 | |
| Bromide SCHEMBL11693374 | 0.77 | SIGMAR1 (0.41) | POLBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073846-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-04-17 | — | — | US | disclosed |
| EP-1292564-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001062705-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073846-A1 | Aminoalcohol derivatives | XDH, ADH1A, ADRB1 | CA2 919/4885HSD17B2 77/4885CA1 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.